<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365154</url>
  </required_header>
  <id_info>
    <org_study_id>010-031</org_study_id>
    <nct_id>NCT03365154</nct_id>
  </id_info>
  <brief_title>Feasibility Clinical Trial of the Cardio Flow Orbital Atherectomy System to Treat Peripheral Artery Disease (PAD)</brief_title>
  <acronym>FAST</acronym>
  <official_title>Feasibility Clinical Trial of the Cardio Flow FreedomFlow Orbital Atherectomy System to Treat Peripheral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio Flow, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Libra Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardio Flow, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a First in Human early feasibility study of a novel atherectomy device to treat&#xD;
      peripheral artery disease. The trial is a prospective, single arm design that will enroll 10&#xD;
      patients at 1 - 2 sites. Patients will be followed at 30 days and 6 months to evaluate vessel&#xD;
      patency following treatment. Safety will be assessed by monitoring adverse events throughout&#xD;
      the study. Safety and Efficacy will be evaluated by comparing study results to established&#xD;
      performance criteria,&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Feasibility Clinical Trial of the Cardio Flow FreedomFlow™ Orbital Atherectomy System to&#xD;
      Treat Peripheral Artery Disease (FAST Trial) is a prospective non-randomized single arm study&#xD;
      that will enroll up to 10 patients at 1 - 2 sites. The study will evaluate the safety and&#xD;
      effectiveness of the Cardio Flow atherectomy device for plaque removal in de novo target&#xD;
      lesions in the peripheral vasculature of the lower extremities. The primary safety endpoint&#xD;
      is defined as freedom from a composite of new onset major adverse events through the 30-day&#xD;
      follow-up as adjudicated by an independent Clinical Events physician. The primary&#xD;
      effectiveness endpoint is defined as the ability of the Cardio Flow Device to achieve a&#xD;
      residual diameter stenosis ≤ 50% without adjunctive therapy, determined by Angiographic core&#xD;
      lab evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Actual">November 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 22, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive Therapy</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Achievement of ≤ 50% residual stenosis without adjunctive therapy as assessed angiographically on a per lesion basis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Free From New-onset Major Adverse Events at 30 Days Post-treatment</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse events include the following:&#xD;
All cause cardiovascular mortality.&#xD;
Myocardial infarction (MI): Any newly diagnosed MI post procedure, defined as CK-MB ≥2X upper limit normal (ULN).&#xD;
Clinically driven target lesion revascularization (TLR): any repeat percutaneous or surgical intervention to treat objectively documented symptoms of recurrent ischemia attributable to the treated lesion.&#xD;
Clinically significant target vessel dissection: NHLBI grade C or greater as confirmed by angiography.&#xD;
Clinically significant target vessel perforation: NHLBI Type III as confirmed by angiography.&#xD;
Unplanned major target limb amputation: Amputation at the level of the trans-metatarsals or higher that was not previously planned&#xD;
Clinically relevant distal embolization: Emboli requiring surgical or medical intervention and/or the presence of symptoms.&#xD;
Pseudoaneurysm: disruption of the arterial wall at the treatment site as confirmed by angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Through six months</time_frame>
    <description>All device and procedure related Serious Adverse Events at 30 days and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lesions With Achievement of ≤ 50% Residual Stenosis With or Without Adjunctive Low-pressure Balloon Therapy</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Ability to achieve &lt;50% residual diameter stenosis with or without adjunctive low-pressure balloon therapy on a per-lesion basis. Operator can follow atherectomy treatment with adjunctive balloon therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment</intervention_name>
    <description>Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Orbital Atherectomy Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Balloon Angioplasty</intervention_name>
    <description>Low pressure balloon angioplasty may be used following atherectomy</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidate for percutaneous endovascular intervention in the lower extremity;&#xD;
&#xD;
          -  Disease is located in peripheral arteries between 2mm and 5mm diameter;&#xD;
&#xD;
          -  Ankle brachial index ≤ 0.90;&#xD;
&#xD;
          -  Rutherford classification 2,3,4 or 5;&#xD;
&#xD;
          -  De novo target lesion has ≥ 50% stenosis;&#xD;
&#xD;
          -  Target lesion length ≤ 200 cm;&#xD;
&#xD;
          -  At least 1 patent tibial vessel runoff;&#xD;
&#xD;
          -  Written, signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female not using adequate contraception or is breastfeeding;&#xD;
&#xD;
          -  Rutherford class 0 1, and 6;&#xD;
&#xD;
          -  target lesion within a native graft,&#xD;
&#xD;
          -  in-stent restenosis,&#xD;
&#xD;
          -  ≤ 50% occlusion, or chronic total occlusion;&#xD;
&#xD;
          -  history of vascular surgery or interventional procedure on index limb within 30 days&#xD;
             prior to procedure, or planned procedure within 30 days after index procedure, lesion&#xD;
             in contralateral limb requiring intervention during index procedure or within 30 days&#xD;
             of index procedure;&#xD;
&#xD;
          -  known or suspected systemic infection;&#xD;
&#xD;
          -  unstable coronary disease; significant kidney disease requiring dialysis;&#xD;
&#xD;
          -  evidence of aneurysmal target vessel within past 2 months;&#xD;
&#xD;
          -  evidence of intracranial or GI bleeding, intracranial aneurysm, MI or stroke within 2&#xD;
             months of baseline evaluation;&#xD;
&#xD;
          -  history of heparin-induced thrombocytopenia;&#xD;
&#xD;
          -  contraindication to anti-platelet, anticoagulant, or thrombolytic therapy;&#xD;
&#xD;
          -  uncorrected bleeding disorders;&#xD;
&#xD;
          -  thrombolytic therapy within 2 weeks of index procedure;&#xD;
&#xD;
          -  life expectancy less than 12 months;&#xD;
&#xD;
          -  unwilling or unable to comply with follow-up requirements;&#xD;
&#xD;
          -  intraoperative complications due to the use of a marketed device prior to use of the&#xD;
             atherectomy system;&#xD;
&#xD;
          -  currently participating in an investigational drug or other device study that has not&#xD;
             completed primary endpoint;&#xD;
&#xD;
          -  unable to tolerate standard interventional procedures if the study device is not&#xD;
             effective.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Zang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Libra Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Research of North Florida, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastlake Cardiovascular, PC</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <results_first_submitted>March 31, 2021</results_first_submitted>
  <results_first_submitted_qc>April 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2021</results_first_posted>
  <disposition_first_submitted>August 23, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 29, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 20, 2021</disposition_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Atherectomy</keyword>
  <keyword>Orbital Atherectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Descriptive statistics of primary and secondary endpoints may be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03365154/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03365154/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.&#xD;
Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.&#xD;
Balloon Angioplasty: Low pressure balloon angioplasty may be used following atherectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.&#xD;
Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.&#xD;
Balloon Angioplasty: Low pressure balloon angioplasty may be used following atherectomy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rutherford Classification</title>
          <description>Rutherford Category is a number scale ranging from 0 to 6 with the following designation:&#xD;
0. Asymptomatic&#xD;
Mild claudication&#xD;
Moderate claudication&#xD;
Severe claudication&#xD;
Ischemic rest pain&#xD;
Minor tissue loss; nonhealing ulcer; local gangrene with diffuse pedal ischemia&#xD;
Major tissue loss extending above trans-metatarsal level</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive Therapy</title>
        <description>Achievement of ≤ 50% residual stenosis without adjunctive therapy as assessed angiographically on a per lesion basis</description>
        <time_frame>At time of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.&#xD;
Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.&#xD;
Balloon Angioplasty: Low pressure balloon angioplasty may be used following atherectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive Therapy</title>
          <description>Achievement of ≤ 50% residual stenosis without adjunctive therapy as assessed angiographically on a per lesion basis</description>
          <units>lesion</units>
          <param>Count of Units</param>
          <units_analyzed>lesion</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesion</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Free From New-onset Major Adverse Events at 30 Days Post-treatment</title>
        <description>Major adverse events include the following:&#xD;
All cause cardiovascular mortality.&#xD;
Myocardial infarction (MI): Any newly diagnosed MI post procedure, defined as CK-MB ≥2X upper limit normal (ULN).&#xD;
Clinically driven target lesion revascularization (TLR): any repeat percutaneous or surgical intervention to treat objectively documented symptoms of recurrent ischemia attributable to the treated lesion.&#xD;
Clinically significant target vessel dissection: NHLBI grade C or greater as confirmed by angiography.&#xD;
Clinically significant target vessel perforation: NHLBI Type III as confirmed by angiography.&#xD;
Unplanned major target limb amputation: Amputation at the level of the trans-metatarsals or higher that was not previously planned&#xD;
Clinically relevant distal embolization: Emboli requiring surgical or medical intervention and/or the presence of symptoms.&#xD;
Pseudoaneurysm: disruption of the arterial wall at the treatment site as confirmed by angiography.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.&#xD;
Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.&#xD;
Balloon Angioplasty: Low pressure balloon angioplasty may be used following atherectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Free From New-onset Major Adverse Events at 30 Days Post-treatment</title>
          <description>Major adverse events include the following:&#xD;
All cause cardiovascular mortality.&#xD;
Myocardial infarction (MI): Any newly diagnosed MI post procedure, defined as CK-MB ≥2X upper limit normal (ULN).&#xD;
Clinically driven target lesion revascularization (TLR): any repeat percutaneous or surgical intervention to treat objectively documented symptoms of recurrent ischemia attributable to the treated lesion.&#xD;
Clinically significant target vessel dissection: NHLBI grade C or greater as confirmed by angiography.&#xD;
Clinically significant target vessel perforation: NHLBI Type III as confirmed by angiography.&#xD;
Unplanned major target limb amputation: Amputation at the level of the trans-metatarsals or higher that was not previously planned&#xD;
Clinically relevant distal embolization: Emboli requiring surgical or medical intervention and/or the presence of symptoms.&#xD;
Pseudoaneurysm: disruption of the arterial wall at the treatment site as confirmed by angiography.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>All device and procedure related Serious Adverse Events at 30 days and 6 months</description>
        <time_frame>Through six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.&#xD;
Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.&#xD;
Balloon Angioplasty: Low pressure balloon angioplasty may be used following atherectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>All device and procedure related Serious Adverse Events at 30 days and 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lesions With Achievement of ≤ 50% Residual Stenosis With or Without Adjunctive Low-pressure Balloon Therapy</title>
        <description>Ability to achieve &lt;50% residual diameter stenosis with or without adjunctive low-pressure balloon therapy on a per-lesion basis. Operator can follow atherectomy treatment with adjunctive balloon therapy.</description>
        <time_frame>At time of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.&#xD;
Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.&#xD;
Balloon Angioplasty: Low pressure balloon angioplasty may be used following atherectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Achievement of ≤ 50% Residual Stenosis With or Without Adjunctive Low-pressure Balloon Therapy</title>
          <description>Ability to achieve &lt;50% residual diameter stenosis with or without adjunctive low-pressure balloon therapy on a per-lesion basis. Operator can follow atherectomy treatment with adjunctive balloon therapy.</description>
          <units>Lesion</units>
          <param>Count of Units</param>
          <units_analyzed>Lesion</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesion</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.&#xD;
Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.&#xD;
Balloon Angioplasty: Low pressure balloon angioplasty may be used following atherectomy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding complication requires transfusion</sub_title>
                <description>GI bleed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Patient scheduled for tracheostomy revision. Received a feeding tube and developed constipation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amputation below the knee</sub_title>
                <description>Left foot/toe pain due to gangrene with amputation of non-treated limb</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Non-healing wound treated with Vancomycin; Anemia requiring transfusion; acute kidney injury in setting of hyperglycemis treated with drugs</description>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Constipation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Routine care visit revealed skin disorder. Treated with Bactrim DS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Non-healing wound treated with Keflex</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Hepatitis C with hepatic steatosis. Discharged and referred to hepatoloogy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Phil Zhang, MD</name_or_title>
      <organization>Libra Medical</organization>
      <phone>6692039308</phone>
      <email>pzhang@libramed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

